<DOC>
	<DOCNO>NCT02209701</DOCNO>
	<brief_summary>Study determine steady-state pharmacokinetics urinary excretion porfiromycin major metabolite head neck cancer cancer patient solid tumor receive radiation therapy .</brief_summary>
	<brief_title>Pharmacokinetic Study Porfiromycin Head Neck Cancer Other Cancer Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Porfiromycin</mesh_term>
	<criteria>Patients histologically proven advanced head neck cancer solid tumor undergo radiation therapy Patients prior chemotherapy consider chemotherapy occur 30 day prior study Patients must receive concomitant radiotherapy ( RT ) Performance status ≥ 70 % Karnofsky performance scale ( KPS ) Must ≥ 18 year age Expected survival least three month Written inform consent Patients meet follow clinical laboratory criterion : Granulocyte count &lt; 2000/mm**3 Platelets &lt; 75,000/mm**3 Serum creatinine &gt; 1.5 time upper limit normal Bilirubin &gt; 1.5 time upper limit normal Prothrombin time partial thromboplastin time &gt; 1.5 time upper limit normal Women pregnant Men woman childbearing potential unwilling utilize medically acceptable method contraception Patients know bleed disorder discretion investigator Presence lifethreatening illness , unstable angina , severe oxygen dependent chronic obstructive pulmonary disease , unstable liver renal disease Treatment granulocyte colonystimulating factor , granulocytemacrophage colonystimulating factor Interleukin1l within 30 day prior start RT Patients prior exposure mitomycin C porfiromycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>